港股異動丨三生製藥(1530.HK)再飈8.55% 年內累計漲幅達68%
格隆匯6月21日丨三生製藥(1530.HK)今日再度大漲8.55%,暫錄三連漲,期間漲幅達20%,年內漲幅更是達到68%,今日高見11.98港元創約一年來新高,最新總市值304億港元。根據聯交所最新權益披露資料顯示,2021年6月15日,三生製藥獲JPMorgan Chase & Co.以每股均價10.5453港元增持好倉約595.44萬股,涉資約6279.13萬港元。增持後,JPMorgan Chase & Co.最新持好倉數目為129,575,692股,持好倉比例由4.85%上升至5.08%。在醫美概念火爆的今年,公司的脱髮產品蔓迪受到市場關注。資料顯示,蔓迪,通用名為米諾地爾酊,2002年作為中國首個非處方脱髮藥品上市,治療男性型脱髮和斑禿。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.